CFTR and cystic fibrosis: CFTR modulators that target the underlying defect, such as the triple combination Elexacaftor/Tezacaftor/Ivacaftor (ETI), are available for approximately 90% of people with cystic fibrosis (pwCF) aged 12 years and older with at least one copy of the del508 mutation.